Oteracil
Teysuno (oteracil) is a small molecule pharmaceutical. Oteracil was first approved as Teysuno on 2011-03-14. It has been approved in Europe to treat stomach neoplasms.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 12 | 12 | — | 1 | 23 |
| Colorectal neoplasms | D015179 | — | 1 | 3 | — | — | 4 | ||
| Head and neck neoplasms | D006258 | — | 1 | 1 | — | — | 2 | ||
| Adenocarcinoma | D000230 | — | 1 | 1 | — | — | 2 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | 1 | |
| Adjuvant chemotherapy | D017024 | — | — | 1 | — | — | 1 | ||
| Carcinoma | D002277 | C80.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 3 | — | — | — | 3 |
| Neoplasms | D009369 | C80 | 1 | 2 | — | — | — | 3 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | 2 | — | — | — | 2 | ||
| Gastrointestinal neoplasms | D005770 | C26.9 | — | 1 | — | — | — | 1 | |
| Bile duct neoplasms | D001650 | — | 1 | — | — | — | 1 | ||
| Pancreatic ductal carcinoma | D021441 | — | 1 | — | — | — | 1 | ||
| Drug therapy | D004358 | 1 | 1 | — | — | — | 1 | ||
| Uterine cervical neoplasms | D002583 | 1 | 1 | — | — | — | 1 | ||
| Nasopharyngeal neoplasms | D009303 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OTERACIL |
| INN | oteracil |
| Description | Tegafur/gimeracil/oteracil, sold under the brand name Teysuno among others is a fixed-dose combination medication used for the treatment of advanced gastric cancer when used in combination with cisplatin, and also for the treatment of head and neck cancer, colorectal cancer, non–small-cell lung, breast, pancreatic, and biliary tract cancers.: 213
|
| Classification | Small molecule |
| Drug class | uracil type antineoplastics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1nc(=O)[nH]c(=O)[nH]1 |
Identifiers
| PDB | — |
| CAS-ID | 937-13-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL181932 |
| ChEBI ID | 30863 |
| PubChem CID | 54715158 |
| DrugBank | DB03209 |
| UNII ID | 5VT6420TIG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,615 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,657 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more